Faeth Therapeutics (FTH) Director Karen Vousden Receives 25,000-Share Award

What Happened

• Karen H. Vousden, a director of Faeth Therapeutics, received a derivative award on 2026-09-11 covering 25,000 shares. The award was reported as an acquisition (code A) at a $0.00 per-share price (total reported value $0.00 on grant). This is a compensation award (an option) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-11; Form 4 filed: 2026-09-15 (filed within two business days, timely).
• Transaction type: Derivative option grant (code A) for 25,000 shares at $0.00 per share.
• Vesting/exercisability: Vests and becomes exercisable in 36 equal monthly installments; fully vested on 2029-09-11, subject to continuous service (see footnote).
• Shares owned after transaction: Not specified in the provided filing.
• Filing accession: 0001723884-26-000005.

Context

• The filing indicates an option-style award that will vest monthly over three years rather than immediately tradable shares. Such grants are common as director compensation and do not by themselves indicate buying or selling activity in the open market. There is no indication the shares were exercised or sold.